Use este identificador para citar ou linkar para este item:
https://repositorio.inpa.gov.br/handle/1/18055
Registro completo de metadados
Campo DC | Valor | Idioma |
---|---|---|
dc.contributor.author | Schmidt, Thomas Jürgen | - |
dc.contributor.author | Khalid, Sami A. | - |
dc.contributor.author | Romanha, Álvaro José | - |
dc.contributor.author | Alves, Tânia Maria de Almeida | - |
dc.contributor.author | Biavatti, Maique Weber | - |
dc.contributor.author | Brun, Reto | - |
dc.contributor.author | Costa, Fernando Batista da | - |
dc.contributor.author | De-Castro, Solange Lisboa | - |
dc.contributor.author | Ferreira, V?tor Francisco | - |
dc.contributor.author | Lacerda, Marcus Vinícius Guimarães de | - |
dc.contributor.author | Lago, João Henriqu Ghilardi | - |
dc.contributor.author | Leon, Leonor Laura Pinto | - |
dc.contributor.author | Lopes, Norberto Peporine | - |
dc.contributor.author | Amorim, Rodrigo César das Neves | - |
dc.contributor.author | Niehues, Michael | - |
dc.contributor.author | Ogungbe, Ifedayo Victor | - |
dc.contributor.author | Pohlit, Adrian Martin | - |
dc.contributor.author | Scotti, M. T. | - |
dc.contributor.author | Setzer, William N. | - |
dc.contributor.author | Soeiro, M. N.C. de | - |
dc.contributor.author | Steindel, Mário R. | - |
dc.contributor.author | Tempone, Andre Gustavo | - |
dc.date.accessioned | 2020-06-15T21:51:16Z | - |
dc.date.available | 2020-06-15T21:51:16Z | - |
dc.date.issued | 2012 | - |
dc.identifier.uri | https://repositorio.inpa.gov.br/handle/1/18055 | - |
dc.description.abstract | Infections with protozoan parasites are a major cause of disease and mortality in many tropical countries of the world. Diseases caused by species of the genera Trypanosoma (Human African Trypanosomiasis and Chagas Disease) and Leishmania (various forms of Leishmaniasis) are among the seventeen "Neglected Tropical Diseases" (NTDs) defined as such by WHO due to the neglect of financial investment into research and development of new drugs by a large part of pharmaceutical industry and neglect of public awareness in high income countries. Another major tropical protozoan disease is malaria (caused by various Plasmodium species), which -although not mentioned currently by the WHO as a neglected disease- still represents a major problem, especially to people living under poor circumstances in tropical countries. Malaria causes by far the highest number of deaths of all protozoan infections and is often (as in this review) included in the NTDs. The mentioned diseases threaten many millions of lives world-wide and they are mostly associated with poor socioeconomic and hygienic environment. Existing therapies suffer from various shortcomings, namely, a high degree of toxicity and unwanted effects, lack of availability and/or problematic application under the life conditions of affected populations. Development of new, safe and affordable drugs is therefore an urgent need. Nature has provided an innumerable number of drugs for the treatment of many serious diseases. Among the natural sources for new bioactive chemicals, plants are still predominant. Their secondary metabolism yields an immeasurable wealth of chemical structures which has been and will continue to be a source of new drugs, directly in their native form and after optimization by synthetic medicinal chemistry. The current review, published in two parts, attempts to give an overview on the potential of such plant-derived natural products as antiprotozoal leads and/or drugs in the fight against NTDs. © 2012 Bentham Science Publishers. | en |
dc.language.iso | en | pt_BR |
dc.relation.ispartof | Volume 19, Número 14, Pags. 2128-2175 | pt_BR |
dc.rights | Restrito | * |
dc.subject | Ageratum Conyzoides Extract | en |
dc.subject | Amphotericin B | en |
dc.subject | Antiprotozoal Agent | en |
dc.subject | Artemisinin | en |
dc.subject | Bergapten | en |
dc.subject | Diterpene | en |
dc.subject | Eflornithine | en |
dc.subject | Eudesmanolide Derivative | en |
dc.subject | Fexinidazole | en |
dc.subject | Gamma Interferon | en |
dc.subject | Germacranolide Derivative | en |
dc.subject | Limonoid | en |
dc.subject | Lupeol | en |
dc.subject | Meglumine Antimonate | en |
dc.subject | Melarsoprol | en |
dc.subject | Miltefosine | en |
dc.subject | Myricetin | en |
dc.subject | Nifurtimox | en |
dc.subject | Parthenolide | en |
dc.subject | Pentamidine | en |
dc.subject | Pentamidine Isethionate | en |
dc.subject | Posaconazole | en |
dc.subject | Quassinoid | en |
dc.subject | Quercetin | en |
dc.subject | Scopoletin | en |
dc.subject | Scyx 7158 | en |
dc.subject | Sesquiterpene Lactone | en |
dc.subject | Stibogluconate Sodium | en |
dc.subject | Suramin | en |
dc.subject | Tafenoquine | en |
dc.subject | Unclassified Drug | en |
dc.subject | Unindexed Drug | en |
dc.subject | Xanthyletin | en |
dc.subject | African Trypanosomiasis | en |
dc.subject | Ageratum Conyzoides | en |
dc.subject | Anaphylaxis | en |
dc.subject | Chagas Disease | en |
dc.subject | Diarrhea | en |
dc.subject | Drug Determination | en |
dc.subject | Drug Fatality | en |
dc.subject | Drug Industry | en |
dc.subject | Drug Megadose | en |
dc.subject | Drug Withdrawal | en |
dc.subject | Enzyme Assay | en |
dc.subject | Fatigue | en |
dc.subject | Fever | en |
dc.subject | Headache | en |
dc.subject | Human | en |
dc.subject | Hygiene | en |
dc.subject | Hypertension | en |
dc.subject | Hypoglycemia | en |
dc.subject | Infection | en |
dc.subject | Leishmania | en |
dc.subject | Leishmaniasis | en |
dc.subject | Malaria | en |
dc.subject | Mortality | en |
dc.subject | Nausea | en |
dc.subject | Nephrotoxicity | en |
dc.subject | Neurological Complication | en |
dc.subject | Neutropenia | en |
dc.subject | Nonhuman | en |
dc.subject | Peripheral Neuropathy | en |
dc.subject | Phase 1 Clinical Trial (topic) | en |
dc.subject | Phase 2 Clinical Trial (topic) | en |
dc.subject | Phase 3 Clinical Trial (topic) | en |
dc.subject | Plasmodium | en |
dc.subject | Plasmodium Falciparum | en |
dc.subject | Seizure | en |
dc.subject | Self Care | en |
dc.subject | Septic Shock | en |
dc.subject | Shock | en |
dc.subject | Socioeconomics | en |
dc.subject | Tanacetum Parthenium | en |
dc.subject | Teratogenicity | en |
dc.subject | Trypanosoma | en |
dc.subject | Vomiting | en |
dc.subject | World Health Organization | en |
dc.subject | Animal | en |
dc.subject | Antiprotozoal Agents | en |
dc.subject | Biological Agents | en |
dc.subject | Humans | en |
dc.subject | Neglected Diseases | en |
dc.subject | Phytotherapy | en |
dc.subject | Plant Extracts | en |
dc.subject | Plants, Medicinal | en |
dc.subject | Protozoan Infections | en |
dc.title | The potential of secondary metabolites from plants as drugs or leads against protozoan neglected diseases - Part I | en |
dc.type | Artigo | pt_BR |
dc.publisher.journal | Current Medicinal Chemistry | pt_BR |
Aparece nas coleções: | Artigos |
Arquivos associados a este item:
Não existem arquivos associados a este item.
Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.